Eli Lilly licenses Peptron’s SmartDepot by October 7?

Foretrace AI research

Understand the odds. Examine the reasoning.

Polymarket shows market prices. Foretrace adds AI probability estimates, opposing evidence and a price-dependent outcome or pass decision for each open market.

Choose a market to analyze 1 open question · Evidence required

24h volume$42.6

Total volume$11.6K

Liquidity$2.9K

Event end date · UTCOct 7, 2026

Price history

Market probability

Loading price history…

Polymarket · UTC

Sampled market observations, not AI forecasts. Lines connect available observations. Legend values are current provider quotes; chart points may be older.

Outcomes & resolution rules

1 market

These are market-implied probabilities, not AI forecasts. A displayed quote may differ from the price available for your order.

Accepting ordersMarket odds6.5%

Eli Lilly licenses Peptron’s SmartDepot by October 7?

Yes6.5%Polymarket estimate

No93.5%Polymarket estimate

Liquidity: $2.9K
Deadline · UTC: Oct 7, 2026
Yes bid / ask: 6.0¢ / 7.0¢
Trading fees: Enabled · verify on Polymarket

Get the Foretrace AI forecast

See a probability estimate with uncertainty, the evidence for and against it, and a conditional decision at the available price.

Fresh successful report: 1 credit. Valid shared report: free.

Resolution rules

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.